This study will evaluate the tolerability and safety of RKI983 ophthalmic solution and explore the effect of the compound on intraocular pressure in subjects with ocular hypertension.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
90
Unnamed facility
Artesia, California, United States
Unnamed facility
Rochester, New York, United States
Unnamed facility
Charlotte, North Carolina, United States
Unnamed facility
Durham, North Carolina, United States
Unnamed facility
Rates of adverse events and serious adverse events, as well as changes in ophthalmic evaluations, laboratory values, ECGs and vital signs over period of 7 days treatment.
Change in ocular hypertension from Baseline to Day 7.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Houston, Texas, United States